| Catalog No. | HF687056 |
| Host species | Humanized |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1-kappa |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact the lab for this information. |
| Expression system | Mammalian Cells |
| Accession | P01031 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternative name | RG-6107, RO7112689, SKY-59, 1917321-26-6 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Research Grade Crovalimab
Overview
Description
Crovalimab (HF687056) is a research-grade recombinant antibody targeting CPAMD4. Produced in mammalian cells with native-like glycosylation.
Highlights
- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Images
 Bioactivity |
SEC-HPLC detection for Research Grade Crovalimab. |
 SDS-PAGE |
SDS-PAGE for Research Grade Crovalimab |